Erratum for vol. 104, p. 3858

In the article by Roberts et al entitled “The use of recombinant factor VIIa in the treatment of bleeding disorders,” which appeared in the December 15, 2004, issue of Blood (Volume 104:3858-3864), the following disclosure was inadvertently omitted by the journal: H.R.R. has been a consultant for and has received an honorarium from Novo Nordisk, the manufacturer of recombinant factor VIIa. He is also a consultant to Baxter Bioscience, which manufactures a competing product, and he has received honoraria from Bayer. G.C.W. is a consultant for and has received honoraria from Baxter Bioscience, Bayer, and Novo Nordisk.